Elan sells EDT unit to Alkermes

By Gareth Macdonald

- Last updated on GMT

Related tags Contract Élan

Elan will sell its delivery technology unit, EDT, to Alkermes in a deal that brings to an end the Irish drugmakers’ long search for a buyer.

The sale, which values EDT at $960m (€660m), will see its range of delivery technologies, contract manufacturing business and in-house drug portfolio merge with Alkermes to form a new organisation in which Elan will hold a 25 per cent stake.

Elan has tried to sell the unit twice​ in the last few years, but on each occasion it failed to find a buyer as a result of "unfavourable market condition​s."

Whether today’s sale means conditions have changed or that Elan has simply accepted a lower bid for EDT is unclear as the firm has never said publicly how much it wanted for the unit.

However, the $960m price tag is well below the $1.4bn Elan was rumoured to have been looking for when it first floated the idea of a sale in 2008​.

Elan spokeswoman Fidelma Callanan told in-Pharmatechniologist.com that: “Today’s transaction is taking place at a time when both businesses are strong and positioned for growth.

Together Alkermes and EDT will create a growing, global CNS company with an exciting future based portfolio of products, pipeline and proprietary technologies​.”

She went on to explain that EDT’s service and supply contracts will not be affected by the divestiture adding that Elan will ensure clients are “kept informed of progress of the transactio​n.”


Callanan also indicated that Elan will continue to play a role in the contract manufacturing services division that EDT launched in last year​.

“In terms of the manufacturing services business, we will continue to promote and seek business, which has been very successful in attracting business opportunities since we launched the new service last Octobe​r.”

This echoes comments made by EDT vice president of manufacturing services operations Philip Pratten during an interview with Outsourcing-pharma.com at Interphex last month​.

Market response

News of the deal, which is due to complete in September, was well received with observers suggesting that it is good for Elan with regard to its strategic objectives.

Adrian Howd, from Berenberg Bank in London told Businessweek that it’s a good deal for the Irish drugmaker explaining that EDT “has never been the crown jewel at Elan. This enables them to restructure the business and to focus on the key value drivers​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more